J9328
J9328 – Injection, temozolomide, 1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 1 NDC crosswalked per 1 MG $10.408/unit ASP+6%
📋 J9328 summary
J9328 is a HCPCS Level II J-code used to bill temozolomide, 1 mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9328: Temodar
Code J9328
Billing unit 1 MG Payment limit $10.408/unit NDC-Crosswalk 1
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9328
DescriptorInjection, temozolomide, 1 mg
Billing unit1 MG
Payment limit / unit$10.408
Est. ASP / unit$9.819 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20
💊 About Temozolomide DRUG GUIDE
Temozolomide treats two types of aggressive brain tumors in adults: glioblastoma and anaplastic astrocytoma.
For newly diagnosed glioblastoma, it is given alongside radiation therapy and then continued as maintenance treatment.For anaplastic astrocytoma, Temodar (the brand-name injection/capsule product) is approved for adjuvant treatment of newly diagnosed cases as well as refractory cases (tumors that have stopped responding to other treatment).
Temozolomide Capsules, USP are approved for newly diagnosed glioblastoma and for refractory anaplastic astrocytoma in patients whose disease progressed on a regimen containing nitrosourea and procarbazine.
Clinical overview from our editorial drug guide for Temozolomide. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$10.408
Est. ASP / unit
$9.819 est.
Est. after 2% sequester
$10.200
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, temozolomide, 1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2010-01-01
Date added2010-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9328 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9328 WITH EST. MEDICARE PAY
1 NDC map to J9328. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($10.408/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00085-1381-01 | TEMODAR Temozolomide 2.5 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Merck | 1 VIAL, SINGLE-USE in 1 CARTON (0085-1381-... | 2.5 mg/mL | 100 | $1,040.80 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$109.5K
Claims
30
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$3,649.32
Trend by period
Where J9328 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #560 of 824
#555
AVYCAZ J0714
$119.7K
#556
EMTRICITABINE-TENOFO... J0750
$118.9K
#557
EVOMELA J9246
$116.9K
#558
ZERBAXA J0695
$112.1K
#559
ETOPOPHOS* J9181
$111.1K
#560
TEMODAR J9328
$109.5K
#561
VIBATIV J3095
$109.2K
#562
ACTIVATE MATRIX, PER... Q4301
$109.2K
#563
EDARAVONE* J1301
$108.3K
#564
AMNIPLY, PER SQ CM** Q4249
$104.2K
#565
AMNICORE PRO, PER SQ... Q4298
$101.8K
Total claims — #742 of 824
#737
ELZONRIS J9269
32
#738
TEPADINA(J9342)* J9342
32
#739
ERZOFRI J2428
31
#740
TIGAN J3250
31
#741
LEVOTHYROXINE SODIUM... J0650
30
#742
TEMODAR J9328
30
#743
CYGNUS, PER SQ CM** Q4170
30
#744
BRIXADI(J0577) J0577
29
#745
HYPERRHO* J2790
29
#746
ZIEXTENZO Q5120
29
#747
HYPERHEP B* 90371
28
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $109.5K | — | 30 | — | $3,649.32 |
| 2025 (Q1-Q4) | $444.3K | 12 | 140 | $37,021.80 | $3,173.30 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$343K
Medicare paid
$268.8K
Submitted services
33,491
Submitted charges
$476.6K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9328 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9328 billing FAQ
What is HCPCS code J9328?
J9328 is a HCPCS Level II J-code used to bill Injection, temozolomide, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9328?
One unit of J9328 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J9328 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9328?
The Medicare Part B payment limit is $10.408 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $10.200 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9328?
1 NDC currently map to J9328 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9328 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.